A Study of Pertuzumab in Participants With Metastatic Breast Cancer

Summary

This study will evaluate the efficacy and safety of pertuzumab (rhuMAb 2C4) in participants with metastatic breast cancer which has progressed during or after standard chemotherapy and which is not amenable to curative therapy. Those who are maintaining a response to therapy or who have stable disease at the end of the formal study period will continue treatment until disease progression or unacceptable toxicity. Approximately 120 participants will be enrolled.

Timeline

Start

2003-02

Primary completion

2005-04

Completion

2005-04

Drugs

Indications